Overview of immunosuppression in liver transplantation

Anjana A. Pillai, Josh Levitsky*

*Corresponding author for this work

Research output: Contribution to journalReview article

58 Citations (Scopus)

Abstract

Continued advances in surgical techniques and immunosuppressive therapy have allowed liver transplantation to become an extremely successful treatment option for patients with end-stage liver disease. Beginning with the revolutionary discovery of cyclosporine in the 1970s, immunosuppressive regimens have evolved greatly and current statistics confirm one-year graft survival rates in excess of 80%. Immunosuppressive regimens include calcineurin inhibitors, anti-metabolites, mTOR inhibitors, steroids and antibody-based therapies. These agents target different sites in the T cell activation cascade, usually by inhibiting T cell activation or via T cell depletion. They are used as induction therapy in the immediate periand post-operative period, as long-term maintenance medications to preserve graft function and as salvage therapy for acute rejection in liver transplant recipients. This review will focus on existing immunosuppressive agents for liver transplantation and consider newer medications on the horizon.

Original languageEnglish (US)
Pages (from-to)4225-4233
Number of pages9
JournalWorld Journal of Gastroenterology
Volume15
Issue number34
DOIs
StatePublished - Dec 7 2009

Fingerprint

Immunosuppressive Agents
Liver Transplantation
Immunosuppression
T-Lymphocytes
Salvage Therapy
End Stage Liver Disease
Graft Survival
Therapeutics
Cyclosporine
Survival Rate
Steroids
Transplants
Antibodies
Liver

Keywords

  • Immunosuppression
  • Induction therapy
  • Liver transplantation
  • Rejection

ASJC Scopus subject areas

  • Gastroenterology

Cite this

@article{b48995eecaec4bb7b3545a098265f36e,
title = "Overview of immunosuppression in liver transplantation",
abstract = "Continued advances in surgical techniques and immunosuppressive therapy have allowed liver transplantation to become an extremely successful treatment option for patients with end-stage liver disease. Beginning with the revolutionary discovery of cyclosporine in the 1970s, immunosuppressive regimens have evolved greatly and current statistics confirm one-year graft survival rates in excess of 80{\%}. Immunosuppressive regimens include calcineurin inhibitors, anti-metabolites, mTOR inhibitors, steroids and antibody-based therapies. These agents target different sites in the T cell activation cascade, usually by inhibiting T cell activation or via T cell depletion. They are used as induction therapy in the immediate periand post-operative period, as long-term maintenance medications to preserve graft function and as salvage therapy for acute rejection in liver transplant recipients. This review will focus on existing immunosuppressive agents for liver transplantation and consider newer medications on the horizon.",
keywords = "Immunosuppression, Induction therapy, Liver transplantation, Rejection",
author = "Pillai, {Anjana A.} and Josh Levitsky",
year = "2009",
month = "12",
day = "7",
doi = "10.3748/wjg.15.4225",
language = "English (US)",
volume = "15",
pages = "4225--4233",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "34",

}

Overview of immunosuppression in liver transplantation. / Pillai, Anjana A.; Levitsky, Josh.

In: World Journal of Gastroenterology, Vol. 15, No. 34, 07.12.2009, p. 4225-4233.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Overview of immunosuppression in liver transplantation

AU - Pillai, Anjana A.

AU - Levitsky, Josh

PY - 2009/12/7

Y1 - 2009/12/7

N2 - Continued advances in surgical techniques and immunosuppressive therapy have allowed liver transplantation to become an extremely successful treatment option for patients with end-stage liver disease. Beginning with the revolutionary discovery of cyclosporine in the 1970s, immunosuppressive regimens have evolved greatly and current statistics confirm one-year graft survival rates in excess of 80%. Immunosuppressive regimens include calcineurin inhibitors, anti-metabolites, mTOR inhibitors, steroids and antibody-based therapies. These agents target different sites in the T cell activation cascade, usually by inhibiting T cell activation or via T cell depletion. They are used as induction therapy in the immediate periand post-operative period, as long-term maintenance medications to preserve graft function and as salvage therapy for acute rejection in liver transplant recipients. This review will focus on existing immunosuppressive agents for liver transplantation and consider newer medications on the horizon.

AB - Continued advances in surgical techniques and immunosuppressive therapy have allowed liver transplantation to become an extremely successful treatment option for patients with end-stage liver disease. Beginning with the revolutionary discovery of cyclosporine in the 1970s, immunosuppressive regimens have evolved greatly and current statistics confirm one-year graft survival rates in excess of 80%. Immunosuppressive regimens include calcineurin inhibitors, anti-metabolites, mTOR inhibitors, steroids and antibody-based therapies. These agents target different sites in the T cell activation cascade, usually by inhibiting T cell activation or via T cell depletion. They are used as induction therapy in the immediate periand post-operative period, as long-term maintenance medications to preserve graft function and as salvage therapy for acute rejection in liver transplant recipients. This review will focus on existing immunosuppressive agents for liver transplantation and consider newer medications on the horizon.

KW - Immunosuppression

KW - Induction therapy

KW - Liver transplantation

KW - Rejection

UR - http://www.scopus.com/inward/record.url?scp=70349562534&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349562534&partnerID=8YFLogxK

U2 - 10.3748/wjg.15.4225

DO - 10.3748/wjg.15.4225

M3 - Review article

C2 - 19750565

AN - SCOPUS:70349562534

VL - 15

SP - 4225

EP - 4233

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 34

ER -